KINLYTIC
LOE ApproachingBLAINJECTIONINJECTABLE
Approved
Jan 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
KINLYTIC by Microbix Biosystems is clinical pharmacology urokinase is an enzyme (protein) produced by the kidney, and found in the urine. Approved for defined, multiple segments. First approved in 1978.
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Kinlytic (urokinase, low molecular weight form) is a fibrinolytic enzyme that converts plasminogen to plasmin, degrading fibrin clots. It is administered intravenously for lysis of pulmonary emboli affecting multiple lung segments. The drug demonstrates superior angiographic and hemodynamic improvement within 24 hours compared to heparin when administered early after symptom onset.
LOE Approaching
Product approaching loss of exclusivity with minimal linked job activity, indicating a consolidating commercial footprint and limited growth opportunities for new hires.
Mechanism of Action
CLINICAL PHARMACOLOGY Urokinase is an enzyme (protein) produced by the kidney, and found in the urine. There are two forms of urokinase which differ in molecular weight but have similar clinical effects. Kinlytic™ is the low molecular weight form. Kinlytic™ acts on the endogenous…
Indications (2)
Worked on KINLYTIC at Microbix Biosystems? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.